Rheumatology Reimbursement Report 2011-2012
A Reimbursement iQ Special ReportHow are rheumatologists changing their treatment practices based on payer
restrictions and reduced reimbursement?
How will payers balance cost containment while still improving compliance and
outcomes measures?
Rheumatology medicines: medical miracles, yes – but a top target for cost-containment. For payers, it’s a hotbed of rising costs and multiple costly biologic therapies, with more expensive new drugs on the horizon. That’s why they’re preparing a host of access-restricting strategies to deal with them.
Meanwhile, physicians want the best for their patients – and their practices. Rheumatologists will adapt to reduced reimbursement in therapy selection and shifting patient site of care.
Don’t try to guess what’s coming in this industry-critical therapeutic area: Get precise data, accurate forecasts and insider insights in Reimbursement Intelligence’s latest report: Rheumatology Reimbursement Report 2011-2012.
The report will cover the latest trial data on new compounds including RA-focused inhibitors of JAK, IL-6, IL-12, SYK, and CD22 antigen, as well as immunomodulators for lupus.
More than just a simple forecast, this report crosschecks past responses with current realities, so you’ll know what payers originally planned, what they ultimately decided and what decisions they’re likely to make in the future. And because it focuses on both payer and physician responses, you’ll understand the real reimbursement environment, where successful marketing strategies take account of how payer and physician actions affect one another… and, of course, the uptake of new medicines.
The result is a reliable, data-based forecast of physicians’ and payers’ plans to contract with, reimburse and prescribe multiple agents, including these players’ views of pressing unmet needs. (And it’s customizable to suit your specific needs.)
ONLY from Reimbursement Intelligence: The Rheumatology Reimbursement Report 2011-2012 is compiled using unique insights from 50 top national and regional health plans and 100 rheumatologists actively prescribing biologics.
These decision-makers will shape the rheumatology landscape in the coming year, and now you canlearn directly from them and make confident, bulletproof decisions about development, positioning, pricing, and marketing for you own records.
The physician and payer data, taken together, will help you clearly understand the different perspectives that will inform product uptake and usage of your in-line and pipeline products, giving you the fundamental understanding and tools you’ll need for – among other things – designing key payer-targeted endpoints into pivotal trials, pricing and launch strategies, physician and payer messaging, and sales force and market access strategies.